Skin adhesion of a newly developed, bioequivalent rotigotine patch formulation in comparison to the originator product: Results of a multi-center, randomized, crossover trial in patients with Parkinson’s disease
Int. Journal of Clinical Pharmacology and Therapeutics · 2025
DOI: 10.5414/cp204672 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Wolfgang H Jost und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Transdermal Patch, Parkinson Disease, Thiophenes, Tetrahydronaphthalenes.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Jost, W. H., Wang, M., Wauer, G., Dax, A., Wedemeyer, R. S., Schug, B., Warnke, A., Leblanc, A., & Schurad, B. (2025). Skin adhesion of a newly developed, bioequivalent rotigotine patch formulation in comparison to the originator product: Results of a multi-center, randomized, crossover trial in patients with Parkinson’s disease. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204672
Vancouver
Jost WH, Wang M, Wauer G, Dax A, Wedemeyer RS, Schug B, et al. Skin adhesion of a newly developed, bioequivalent rotigotine patch formulation in comparison to the originator product: Results of a multi-center, randomized, crossover trial in patients with Parkinson’s disease. Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204672
BibTeX
@article{Jost2025,
author = {Jost, Wolfgang H and Wang, Maggie and Wauer, Gabriel and Dax, Annika and Wedemeyer, Ralph-Steven and Schug, Barbara and Warnke, André and Leblanc, Ana and Schurad, Bjoern},
title = {Skin adhesion of a newly developed, bioequivalent rotigotine patch formulation in comparison to the originator product: Results of a multi-center, randomized, crossover trial in patients with Parkinson’s disease},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2025},
doi = {10.5414/cp204672}
}
EUVIMED